We Point Out One FDA Information Site and One FDA Database, Each of Which Are Good Starting Points
(Posted by Tom Lamb at Drug Injury Watch)
If you or someone you know experienced serious side effects that
Drug Injury Watch
Blog Authors
Latest from Drug Injury Watch
Ukoniq Drug Recall in April 2022 Comes Soon After FDA Warning About Increased Risk of Death in February 2022
By Tom Lamb
This “New” Lymphoma Drug Had Only Been on the Market Since February 2021, When Ukoniq Received FDA Accelerated Approval
(Posted by Tom Lamb at Drug Injury Watch)
In February 2022 we wrote about this Drug Safety Communication,…
Multiple Sclerosis (MS) Drugs Gilenya and Ocrevus Associated With a Higher Likelihood of Melanoma Skin Cancer
By Tom Lamb
Other MS Treatments Such as Lemtrada and Mayzent May Have an Increased Risk of Basal Cell Carcinoma and Squamous Cell Carcinoma
(Posted by Tom Lamb at Drug Injury Watch)
An analysis of skin cancers reported to the…
Fosamax Femur Fracture Federal Court MDL Lawsuits Are Dismissed For a Second Time in March 2022
By Tom Lamb
In a Long-Awaited Opinion, Federal Court Judge Wolfson Rules in Favor of Merck on Federal Preemption Legal Issue
(Posted by Tom Lamb at Drug Injury Watch)
On March 23, 2022, the federal court product liability lawsuits filed…
Ukoniq FDA Advisory Committee Meeting in April 2022 Will Evaluate Ukoniq Drug Safety Findings
By Tom Lamb
FDA Has Been Investigating Ukoniq for an Increased Risk of Death in Lymphoma Cancer Patients Treated With Ukoniq
(Posted by Tom Lamb at Drug Injury Watch)
In early February 2022 we learned this Drug Safety Communication, “…
Novartis Finally Issues Revised Beovu Prescribing Information for US in February 2022
By Tom Lamb
Meaning as Regards Beovu Safety Issues by a Comparison of Major Changes Made: “Revised: 2/2022” vs. “Revised: 6/2020”
(Posted by Tom Lamb at Drug Injury Watch)
Beovu (brolucizumab) was approved by the FDA in 2019 as a…
How People Can Report Adverse Drug Reactions to the FDA, and What Happens to This Information Thereafter
By Tom Lamb
A Brief Introduction for Patients to (1) the FDA MedWatch Program, and (2) the FDA Adverse Event Reporting System
(Posted by Tom Lamb at Drug Injury Watch)
From time to time we hear from people who want…
JAK Inhibitors Safety Review by European Drug Regulator EMA Announced in February 2022
By Tom Lamb
Xeljanz, Rinvoq, and Olumiant as Treatments for Inflammatory Disorders Have Been Under Scrutiny by FDA in the US
(Posted by Tom Lamb at Drug Injury Watch)
In December 2021 there was a notable JAK inhibitors drug class…
Ukoniq Lymphoma Drug Safety Investigation Started In February 2022 to Examine Increased Risk of Death
By Tom Lamb
FDA Oncologic Drugs Advisory Committee Meeting in Near Future May Consider Possible Ukoniq Drug Recall
We learned in early February 2022 about an FDA investigation of Ukoniq (umbralisib) after a so-called “safety signal” indicated an association between Ukoniq and increased…
Xeljanz Safety Study Final Data Details the Increased Risks of Cancers and Major Adverse Cardiovascular Events
By Tom Lamb
January 2022 Medical Journal Article Presents Full Set of Findings for the Xeljanz “ORAL Surveillance” Trial Which Started in 2014
(Posted by Tom Lamb at Drug Injury Watch)
One year ago Pfizer released some preliminary results from…